These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28795581)

  • 1. The evolution of the Pharma-CRO working relationship: AstraZeneca and Covance.
    Bioanalysis; 2017 Aug; 9(15):1171-1174. PubMed ID: 28795581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of bioanalytical outsourcing: a pharma perspective.
    Bioanalysis; 2017 Aug; 9(15):1165-1169. PubMed ID: 28795582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AstraZeneca and Covance Laboratories Clinical Bioanalysis Alliance: an evolutionary outsourcing model.
    Arfvidsson C; Severin P; Holmes V; Mitchell R; Bailey C; Cape S; Li Y; Harter T
    Bioanalysis; 2017 Aug; 9(15):1181-1194. PubMed ID: 28762755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changing world of bioanalysis: summary of panel discussions.
    Spooner N; Anderson M; Dillen L; Ferrari L; Hilhorst M; Lam Z; Michi M; Munday J; Smeraglia J; Summerfield S; Zimmer D
    Bioanalysis; 2017 Aug; 9(15):1175-1179. PubMed ID: 28763241
    [No Abstract]   [Full Text] [Related]  

  • 5. Outsourcing in bioanalysis: a CRO perspective.
    Lowes S
    Bioanalysis; 2017 Aug; 9(15):1161-1164. PubMed ID: 28829186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the China Bioanalytical Forum: interview with Daniel Tang.
    Tang D
    Bioanalysis; 2017 Feb; 9(4):333-335. PubMed ID: 28102698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioanalytical outsourcing: transitioning from Pharma to CRO.
    Hayes R
    Bioanalysis; 2017 Aug; 9(15):1149-1152. PubMed ID: 28763257
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of a collaborative tool to simplify the outsourcing of preclinical safety studies: an insight into the AstraZeneca-Charles River Laboratories strategic relationship.
    Martin FDC; Benjamin A; MacLean R; Hollinshead DM; Landqvist C
    Drug Discov Today; 2017 Dec; 22(12):1754-1759. PubMed ID: 28851537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outsourcing of bioanalysis at GSK: a hybrid approach with a robust support model.
    Abberley L
    Bioanalysis; 2017 Aug; 9(15):1139-1144. PubMed ID: 28762760
    [No Abstract]   [Full Text] [Related]  

  • 10. Outsourcing lead optimization: the eye of the storm.
    Clark DE
    Drug Discov Today; 2011 Feb; 16(3-4):147-57. PubMed ID: 21145413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopharma CRO industry in China: landscape and opportunities.
    Xia C; Gautam A
    Drug Discov Today; 2015 Jul; 20(7):794-8. PubMed ID: 25701282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A community of practice approach to bioanalysis delivery: the role of the Preclinical Bioanalysis and Toxicokinetics department at AstraZeneca.
    Wilson A; Silvester S; Woods K
    Bioanalysis; 2014 May; 6(10):1329-37. PubMed ID: 24958117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving Outsourcing Landscape in Pharma R&D: Different Collaborative Models and Factors To Consider When Choosing a Contract Research Organization.
    DeCorte BL
    J Med Chem; 2020 Oct; 63(20):11362-11367. PubMed ID: 32479727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conference report: a hitchhiker's guide to outsourcing ADME studies: the inside of outsourcing.
    Pritchard JF; Anderson SR; Breuckner C; Premkumar ND; Polli JW
    Bioanalysis; 2013 Feb; 5(4):403-5. PubMed ID: 23414372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quiet revolution: outsourcing in pharma.
    Crossley R
    Drug Discov Today; 2004 Aug; 9(16):694. PubMed ID: 15341780
    [No Abstract]   [Full Text] [Related]  

  • 16. Outsourcing bioanalytical services at Janssen Research and Development: the sequel anno 2017.
    Dillen L; Verhaeghe T
    Bioanalysis; 2017 Aug; 9(15):1195-1201. PubMed ID: 28762758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioanalytical method transfer considerations of chromatographic-based assays.
    Williard CV
    Bioanalysis; 2016 Jul; 8(13):1409-13. PubMed ID: 27277876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing shape: evolving an outsourced bioanalytical strategy to support the changing needs of drug development.
    Stovold C; Milligan F; Hawthorne G; Pattison C; Wilson A
    Bioanalysis; 2017 Aug; 9(15):1135-1137. PubMed ID: 28763237
    [No Abstract]   [Full Text] [Related]  

  • 19. Outsourcing to exploit a key asset.
    Meerpoel L; Schroven M; Goris K; Demoen K; Marsden S
    Drug Discov Today; 2006 Jun; 11(11-12):556-60. PubMed ID: 16713908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on the draft ICH M10 guidance: an interview with Kelly Dong.
    Dong K
    Bioanalysis; 2019 Nov; 11(22):2025-2026. PubMed ID: 31645114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.